GlassScriptPhysician profile
Martin Melson
NPI 1265978944
$3,435.48
in general payments reported to CMS, 2019-2025
25 companies · $712 in 2025
The $712 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $411 · 2023: $791 · 2024: $1,521 · 2025: $712.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,024.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $600.78 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $354.16 | 2023-2025 | Farxiga, Breztri |
| Sanofi-Aventis U.S. LLC | $335.24 | 2024-2025 | |
| Exact Sciences Corporation | $311.35 | 2023-2025 | Cologuard Collection Kit |
| Abbvie INC. | $267.27 | 2022-2025 | |
| Idorsia Pharmaceuticals US INC | $187.49 | 2024 | Quviviq |
| Astellas Pharma US INC | $185.87 | 2023-2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $143.38 | 2022-2024 | |
| Medtronic, INC. | $132.99 | 2024 | Endurant Iis |
| Pfizer INC. | $127.47 | 2023-2025 | |
| Axsome Therapeutics, INC. | $125.00 | 2024 | Auvelity |
| Glaxosmithkline, LLC. | $108.01 | 2023 | Arexvy |
| Lilly USA, LLC | $94.75 | 2022-2025 | Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.87 | 2022-2024 | Tradjenta, Jardiance |
| Sumitomo Pharma America, INC. | $72.36 | 2023-2025 | Gemtesa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $68.24 | 2022-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $45.36 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $33.84 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Kowa Pharmaceuticals America, INC. | $27.59 | 2023 | Seglentis |
| Amgen INC. | $26.35 | 2024 | Otezla, Repatha |
| Gilead Sciences, INC. | $22.93 | 2025 | |
| Atricure, INC. | $22.28 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.05 | 2024 | Camzyos |
| Tactile Systems Technology INC | $19.93 | 2025 | Nimbl, Flexitouch Plus |
| Akebia Therapeutics INC | $17.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Melson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.